Observe aseptic technique & standard practice to prevent cross-infections. Do not inj intravascularly. Immediately stop inj in case of changes in vision, signs of stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Do not use in case of active disease eg, inflammation, infection or tumours, in or near the intended treatment site until the disease has been controlled. Do not resterilize. Caution in immunosuppressed patients. Exercise special caution when treating areas in close proximity to permanent implant; & if patient has undergone prior surgical procedure in the planned treatment area. Avoid too large or too superficial inj in treating facial areas w/ limited soft tissue support or soft tissue cover. Risk of reactivation of latent or subclinical herpes viral infections. Caution in patients who have undergone therapy w/ thrombolytics, anticoagulants, or inhibitors of platelet aggregation, in the preceding 2 wk. Risk of keloid formation in individuals w/ skin types IV-VI. Do not inj into an area where an implant of non-hyaluronic acid has been placed. Avoid excessive sun or extreme cold at least until any initial swelling & redness has resolved. Theoretical risk of inflammation at the implant site if laser treatment, chemical peeling or any other procedure based on active dermal response is performed after implantation; or if the product is administered before skin has completely healed after such a procedure. Has not been tested in pregnant or breastfeeding women or in childn. Lidocaine: Consider total dose of lidocaine administered if dental block or topical administration of lidocaine is concurrently used. Caution w/ concomitant use of other local anaesth or agents structurally related to amide-type local anaesth. Caution in patients w/ epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction. Peribulbar inj of local anaesth carry a low risk of persistent ocular muscle dysfunction.
Sign Out
